The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients [PDF]
Cancer Immunology, Immunotherapy, 2023 Abstract Introduction PD-L1 (Programmed Cell Death Ligand 1) is currently the only recognised marker of response to immunotherapy with anti-PD-1 or anti-PD-L1 antibodies in patients with advanced non-small cell lung cancer (NSCLC). However, this marker is not perfect.
Chmielewska, Izabela +6 more
openaire +4 more sources
Can sPD-1 and sPD-L1 Plasma Concentrations Predict Treatment Response among Patients with Extraparenchymal Neurocysticercosis? [PDF]
Pathogens, 2023 Extraparenchymal neurocysticercosis (EP-NC) is a chronic, potentially life-threatening disease that responds poorly to initial anthelmintic drug therapy.
Edda Sciutto +5 more
core +2 more sources
Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity [PDF]
Journal of Immunology Research, 2022 COVID-19 has several mechanisms that can lead to lymphocyte depletion/exhaustion. The checkpoint inhibitor molecule programmed death protein 1 (PD-1) and its programmed death-ligand 1 (PDL-1) play an important role in inhibiting cellular activity as well as the depletion of these cells.
Danielle Rosa Beserra +9 more
openaire +4 more sources
Sex-dependent PD-L1/sPD-L1 trafficking in human endothelial cells in response to inflammatory cytokines and VEGF [PDF]
Biomedicine & Pharmacotherapy, 2023 Programmed cell death 1 ligand 1 (PD-L1) expressed in non-immune cells is involved in immune-mediated tissue damage in the context of inflammatory conditions and tumor immune escape. Emerging evidence suggests soluble (s)PD-L1 as a marker of inflammation.
Paolo Sfriso +15 more
core +4 more sources
Higher serum sPD-L1 levels after radiotherapy indicate poor outcome in hepatocellular carcinoma patients [PDF]
Translational Oncology, 2022 Our preclinical research reveals that radiotherapy (RT) promoted PD-L1 upregulation in tumor tissues and that higher PD-L1 after RT worsened the prognosis through immunosuppression. We sought to validate our experimental results in clinical cohorts and promote clinical application.In cohort 1, formalin-fixed paraffin-embedded samples were obtained from
Yang Zhang +6 more
openaire +4 more sources
“Role of kidney function and concentrations of BAFF, sPD-L1 and sCD25 on mortality in hospitalized patients with COVID-19” [PDF]
BMC Nephrology, 2022 Abstract Background Chronic kidney disease (CKD) is a recognized risk factor for severe complications in COVID-19. Our objective was to analyze the association between kidney function / T and B lymphocyte modulatory factors and risk of mortality in COVID-19 patients. Methods
Ladan Mansouri +5 more
openaire +4 more sources
Cancer Urology, 2022 Background. The search for new prognostic markers of renal cell carcinoma is an urgent problem of oncourology. Modern studies demonstrate the need for a comprehensive assessment of the clinical and prognostic significance of many markers.Aim is a ...
S. D. Bezhanova +13 more
core +2 more sources
Soluble programmed death ligand-1(sPD-L1) is elevated in aggressive prostate cancer disease among African men [PDF]
Oncology and Therapy, 2021 Abstract Background The programmed death 1 (PD1)/programmed death-ligand 1 (PDL1) targeted immunotherapies have become a new mode of treatment for several tumours; however, there is limited evidence on the expression and prognostic value of PD1/PDL1 in prostate cancer, especially in African men.
Paul Katongole +10 more
openaire +3 more sources
The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer [PDF]
Front Immunol, 2022 Accumulating evidence suggests that regulatory B cells (Bregs) play important roles in inhibiting the immune response in tumors. Programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) are important molecules that maintain the balance of the ...
Qin Wang +12 more
core +2 more sources
Expression levels of STAT3, and protein levels of IL‑6 and sPD‑L1 in different pathological characteristics of endometrial adenocarcinomas [PDF]
Oncology LettersEndometrial cancer is a common type of cancer in women, with endometrial adenocarcinoma (EA) being the most common type. Monitoring the expression levels of signal transducer and activator of transcription 3 (STAT3), the protein levels of interleukin 6 (IL-6) and soluble programmed death ligand 1 (sPD-L1), and their differences in patients with various
Ma, Chunxing +7 more
openaire +3 more sources